Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
asco   save search
Biomica to Present at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
Published: 2024-04-16 (Crawled : 14:00) - biospace.com/
EVGN | $0.7 -13.64% 63K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
meeting
Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024
Published: 2024-04-05 (Crawled : 12:00) - globenewswire.com
LIPO | $0.707 -0.88% -0.89% 6.4K twitter stocktwits trandingview |
| | O: -0.6% H: 6.74% C: 6.74%
candidate asco pharmaceuticals preclinical for
MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)
Published: 2024-04-02 (Crawled : 23:00) - globenewswire.com
MNOV | $1.395 -0.36% -0.36% 18K twitter stocktwits trandingview |
Health Technology
 | | O: 2.01% H: 4.61% C: 0.0%
mn-166 presentation meeting trial results glioblastoma
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer
Published: 2024-04-01 (Crawled : 13:00) - globenewswire.com
CYCC | $1.85 -5.38% 10K twitter stocktwits trandingview |
Health Technology
 | | O: 4.27% H: 0.0% C: -5.45%
precision asco cancer pharmaceuticals meeting potential
ARMOUR Residential REIT, Inc. Names Sergey Losyev and Desmond Macauley as Co-Chief Investment Officers
Published: 2024-03-18 (Crawled : 22:00) - globenewswire.com
ARR | $18.17 2.6% 0.0% 970K twitter stocktwits trandingview |
Finance
 | | O: -0.27% H: 1.39% C: 1.34%
HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session
Published: 2024-02-07 (Crawled : 00:00) - globenewswire.com
HCM | $16.49 0.8% 0.79% 61K twitter stocktwits trandingview |
Health Technology
 | | O: 0.0% H: 1.85% C: 1.41%
presentation asco cancer series
Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium
Published: 2024-01-26 (Crawled : 22:00) - prnewswire.com
AADI | $1.835 1.94% 1.91% 140K twitter stocktwits trandingview |
Manufacturing
 | Email alert Add to watchlist
symposium bioscience
CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024
Published: 2024-01-26 (Crawled : 12:30) - globenewswire.com
CRBP | $39.12 7.09% 6.62% 280K twitter stocktwits trandingview |
Health Technology
 | | O: 98.82% H: 0.0% C: 0.0%
crb-701 drug antibody tumors positive study
Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024
Published: 2024-01-25 (Crawled : 22:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M twitter stocktwits trandingview |
Health Technology
 | | O: -0.27% H: 0.07% C: -0.07%
EXEL | $22.51 0.09% 0.09% 2.3M twitter stocktwits trandingview |
Health Technology
 | | O: 0.14% H: 1.4% C: -0.23%
ntact-02 asco cancer trial results
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium
Published: 2024-01-25 (Crawled : 20:00) - biospace.com/
EPIX | $6.57 -2.23% -2.28% 100K twitter stocktwits trandingview |
Health Technology
 | | O: 0.46% H: 3.06% C: -22.99%
epi-7386 pharma symposium asco
Johnson & Johnson Highlights Ambition to Transform the Treatment of Prostate Cancer and Bladder Cancer through Data Presentations at ASCO GU
Published: 2024-01-24 (Crawled : 14:30) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M twitter stocktwits trandingview |
Health Technology
 | | O: -0.32% H: 0.0% C: 0.0%
asco bladder cancer treatment
Phase 1 Clinical Data for SYS6002 (CRB-701) to be presented at 2024 ASCO GU
Published: 2024-01-23 (Crawled : 13:00) - globenewswire.com
CRBP | $39.12 7.09% 6.62% 280K twitter stocktwits trandingview |
Health Technology
 | | O: 5.13% H: 0.25% C: -8.64%
sys6002 asco
Latest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024
Published: 2024-01-22 (Crawled : 22:00) - globenewswire.com
TAK | News | $13.24 0.61% 0.0% 1.3M twitter stocktwits trandingview |
Health Technology
 | | O: -0.14% H: 0.17% C: -0.27%
cabometyx asco immunotherapy trial
Botensilimab/Balstilimab Breakthrough Data Presented at ASCO-GI Shows Unprecedented Tumor Shrinkage and Robust Biomarker Response in Prevalent Colorectal Cancer Population
Published: 2024-01-22 (Crawled : 13:30) - biospace.com/
AGEN | $5.3 6.64% 6.23% 1.5M twitter stocktwits trandingview |
Health Technology
 | | O: 12.46% H: 1.52% C: -9.46%
biomarker cancer tumor response
Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium
Published: 2024-01-19 (Crawled : 22:00) - prnewswire.com
AADI | $1.835 1.94% 1.91% 140K twitter stocktwits trandingview |
Manufacturing
 | Email alert Add to watchlist
symposium bioscience gastrointestinal
Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium
Published: 2024-01-18 (Crawled : 21:00) - globenewswire.com
CHRS | $2.06 3.0% 2.91% 2.9M twitter stocktwits trandingview |
Health Technology
 | | O: 5.0% H: 1.59% C: -3.17%
il-27 symposium asco positive
Guardant Health to present data at ASCO GI supporting use of liquid biopsy to predict colon cancer recurrence
Published: 2024-01-17 (Crawled : 14:00) - biospace.com/
GH M | $16.08 -3.54% -3.67% 1.9M twitter stocktwits trandingview |
Health Services
 | | O: -2.21% H: 3.0% C: 2.48%
health asco cancer colon
Bristol Myers Squibb Data at ASCO GU 2024 Showcase Transformative Research in the Treatment of Genitourinary Cancers
Published: 2024-01-17 (Crawled : 14:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M twitter stocktwits trandingview |
Health Technology
 | | O: -0.9% H: 1.05% C: 0.87%
asco treatment research
Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium
Published: 2024-01-17 (Crawled : 13:30) - globenewswire.com
ELTX | $8.465 2.86% 2.78% 28K twitter stocktwits trandingview |
| | O: 1.89% H: 0.0% C: -5.58%
eli-002 vaccine symposium asco trial therapeutics study
Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium
Published: 2024-01-16 (Crawled : 22:00) - prnewswire.com
LPTX | $2.81 -5.07% -5.34% 200K twitter stocktwits trandingview |
Health Technology
 | | O: -1.73% H: 2.05% C: -2.93%
symposium asco leap gastrointestinal therapeutics study
Gainers vs Losers
67% 33%

Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M twitter stocktwits trandingview |
Finance
EGOX | $0.0515 43.06% 30.1% 330M twitter stocktwits trandingview |

OLB 4 | $0.33 -14.95% 25.53% 840K twitter stocktwits trandingview |
Technology Services
NVFY | $2.77 31.28% 23.83% 33M twitter stocktwits trandingview |
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M twitter stocktwits trandingview |
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M twitter stocktwits trandingview |
Distribution Services
INSG | $3.03 25.21% 20.13% 330K twitter stocktwits trandingview |
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K twitter stocktwits trandingview |
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M twitter stocktwits trandingview |

ASNS | $0.828 21.75% 17.86% 18K twitter stocktwits trandingview |

Your saved searches
Save your searches and get alerts when important news are released.